Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

[1]  Anne M Johnson,et al.  Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients , 2007, Journal of acquired immune deficiency syndromes.

[2]  M. Kozal,et al.  Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies , 2007, AIDS.

[3]  Evan Wood,et al.  Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy , 2007, AIDS.

[4]  Gitte Pedersen,et al.  Survival of Persons with and without HIV Infection in Denmark, 19952005 , 2007, Annals of Internal Medicine.

[5]  S. Twu,et al.  Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. , 2006, QJM : monthly journal of the Association of Physicians.

[6]  Evan Wood,et al.  The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic , 2006, The Lancet.

[7]  Jonathan A C Sterne,et al.  HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis , 2006, The Lancet.

[8]  Milton C Weinstein,et al.  The survival benefits of AIDS treatment in the United States. , 2006, The Journal of infectious diseases.

[9]  J. Sterne,et al.  Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries , 2006, The Lancet.

[10]  Evan Wood,et al.  Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia , 2006, AIDS.

[11]  Mark R Wallace,et al.  Comparisons of Causes of Death and Mortality Rates Among HIV-Infected Persons: Analysis of the Pre-, Early, and Late HAART (Highly Active Antiretroviral Therapy) Eras , 2006, Journal of acquired immune deficiency syndromes.

[12]  Joel E Gallant,et al.  Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. , 2006, The New England journal of medicine.

[13]  Jonathan AC Sterne,et al.  Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study , 2005, The Lancet.

[14]  R. Hogg,et al.  There and back again: the impact of adult HIV prevalence on national life expectancies , 2005, HIV medicine.

[15]  P. Morlat,et al.  Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. , 2004, International journal of epidemiology.

[16]  H. Furrer,et al.  Migrants from sub-Saharan Africa in the Swiss HIV Cohort Study: a single center study of epidemiologic migration-specific and clinical features. , 2004, AIDS patient care and STDs.

[17]  Shui-Shan Lee,et al.  Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  J. Sterne,et al.  Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy , 2004, Statistics in medicine.

[19]  Michael S Saag,et al.  Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel , 2006 .

[20]  B. Gazzard,et al.  Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study , 2004, The Lancet.

[21]  Victor De Gruttola,et al.  Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. , 2003, The New England journal of medicine.

[22]  J. Lange.  Efficacy and Durability of Nevirapine in Antiretroviral Drug Naïve Patients , 2003, Journal of acquired immune deficiency syndromes.

[23]  J. Sterne,et al.  Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies , 2003, The Lancet.

[24]  Mark S Roberts,et al.  Long-Term HIV/AIDS Survival Estimation in the Highly Active Antiretroviral Therapy Era , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.

[25]  Jonathan AC Sterne,et al.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.

[26]  D. Neau,et al.  Causes of death among HIV‐infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998–1999 , 2002, HIV medicine.

[27]  M. Lederman,et al.  Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995--1999. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  M. Kazatchkine,et al.  Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy , 2000, Annals of Internal Medicine.

[29]  K. Tashima,et al.  Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. , 1999, The New England journal of medicine.

[30]  R. Chaisson,et al.  Natural history of HIV infection in the era of combination antiretroviral therapy. , 1999, AIDS.

[31]  M. Chiasson,et al.  Declining HIV/AIDS mortality in New York City. , 1999, Journal of acquired immune deficiency syndromes.

[32]  E. Vittinghoff,et al.  Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. , 1999, The Journal of infectious diseases.

[33]  JD Lundgren,et al.  Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.

[34]  A Muñoz,et al.  Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.

[35]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[36]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[37]  R. Hogg,et al.  Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. , 1998, JAMA.

[38]  Manuel Battegay,et al.  Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study , 1997, BMJ.

[39]  S. Chu,et al.  Years of potential life lost due to HIV infection in the United States , 1997, AIDS.

[40]  B. Yip,et al.  Decline in deaths from AIDS due to new antiretrovirals , 1997, The Lancet.

[41]  O. Gefeller,et al.  Years of potential life lost (YPLL)--what does it measure? , 1991, Epidemiology.

[42]  R. Grant,et al.  Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users , 2002, Journal of General Internal Medicine.